HealthCor Management L.P. increased its stake in Intersect ENT Inc (NASDAQ:XENT) by 53.7% in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 1,950,000 shares of the medical equipment provider’s stock after purchasing an additional 681,150 shares during the quarter. Intersect ENT comprises about 1.9% of HealthCor Management L.P.’s holdings, making the stock its 24th largest position. HealthCor Management L.P. owned 6.38% of Intersect ENT worth $56,063,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. PNC Financial Services Group Inc. grew its position in shares of Intersect ENT by 2,091.8% in the second quarter. PNC Financial Services Group Inc. now owns 6,707 shares of the medical equipment provider’s stock valued at $252,000 after purchasing an additional 6,401 shares in the last quarter. Tekla Capital Management LLC purchased a new position in shares of Intersect ENT in the third quarter valued at $240,000. Bluefin Trading LLC purchased a new position in shares of Intersect ENT in the third quarter valued at $269,000. Man Group plc grew its position in shares of Intersect ENT by 32.2% in the third quarter. Man Group plc now owns 10,289 shares of the medical equipment provider’s stock valued at $296,000 after purchasing an additional 2,509 shares in the last quarter. Finally, Cubist Systematic Strategies LLC grew its position in shares of Intersect ENT by 322.1% in the second quarter. Cubist Systematic Strategies LLC now owns 12,519 shares of the medical equipment provider’s stock valued at $469,000 after purchasing an additional 9,553 shares in the last quarter. Institutional investors own 91.66% of the company’s stock.

Intersect ENT stock opened at $30.60 on Friday. Intersect ENT Inc has a 52 week low of $25.15 and a 52 week high of $42.95. The stock has a market cap of $983.88 million, a P/E ratio of -54.64 and a beta of 0.58.

Intersect ENT (NASDAQ:XENT) last posted its earnings results on Monday, November 5th. The medical equipment provider reported ($0.25) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.27) by $0.02. Intersect ENT had a negative return on equity of 17.62% and a negative net margin of 20.00%. The business had revenue of $24.70 million during the quarter, compared to analysts’ expectations of $24.09 million. During the same period in the previous year, the business earned ($0.15) earnings per share. The firm’s revenue was up 10.8% on a year-over-year basis. As a group, equities research analysts predict that Intersect ENT Inc will post -0.73 EPS for the current year.

In related news, insider Lisa D. Earnhardt sold 20,000 shares of the business’s stock in a transaction dated Thursday, November 15th. The stock was sold at an average price of $30.01, for a total transaction of $600,200.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Jeryl L. Hilleman sold 12,833 shares of Intersect ENT stock in a transaction dated Monday, October 8th. The stock was sold at an average price of $27.99, for a total value of $359,195.67. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 72,833 shares of company stock valued at $2,134,796. 5.90% of the stock is owned by company insiders.

Several equities analysts recently commented on XENT shares. BidaskClub upgraded Intersect ENT from a “sell” rating to a “hold” rating in a research report on Saturday, December 8th. ValuEngine upgraded Intersect ENT from a “hold” rating to a “buy” rating in a research report on Tuesday, October 2nd. Northland Securities restated a “hold” rating and set a $28.00 target price on shares of Intersect ENT in a research report on Wednesday, October 17th. Finally, Zacks Investment Research upgraded Intersect ENT from a “hold” rating to a “buy” rating and set a $30.00 target price for the company in a research report on Wednesday, November 7th. Three equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. Intersect ENT presently has an average rating of “Buy” and a consensus target price of $36.50.

TRADEMARK VIOLATION NOTICE: “HealthCor Management L.P. Buys 681,150 Shares of Intersect ENT Inc (XENT)” was posted by Daily Political and is the property of of Daily Political. If you are reading this report on another site, it was stolen and republished in violation of international trademark and copyright legislation. The legal version of this report can be read at https://www.dailypolitical.com/2018/12/16/healthcor-management-l-p-buys-681150-shares-of-intersect-ent-inc-xent.html.

About Intersect ENT

Intersect ENT, Inc, a drug delivery company, researches and develops products for the treatment of patients with ear, nose and throat conditions in the United States. It offers PROPEL and PROPEL mini drug releasing implants for patients undergoing sinus surgery to treat chronic sinusitis; and PROPEL Contour, a steroid releasing implant to frontal and maxillary sinus ostia, or openings, of the dependent sinuses.

Read More: What is Cost of Debt?

Institutional Ownership by Quarter for Intersect ENT (NASDAQ:XENT)

Receive News & Ratings for Intersect ENT Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intersect ENT and related companies with MarketBeat.com's FREE daily email newsletter.